{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:17:04Z","timestamp":1787847424843,"version":"build-2784847793"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.4103\/ijd.ijd_794_19","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:52:07Z","timestamp":1623156727000},"page":"208-210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Superimposed Effects of Adalimumab and Linagliptin on the Development of Bullous Pemphigoid in a Psoriatic Patient"],"prefix":"10.4103","volume":"66","author":[{"given":"Katsuhiro","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20240829","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000243805","article-title":"Bullous pemphigoid during long-term TNF-\u03b1 blocker therapy","volume":"219","author":"Bordignon","year":"2009","journal-title":"Dermatology"},{"key":"R2-21-20240829","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000443330","article-title":"Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors-one due to linagliptin","volume":"232","author":"Mendon\u00e7a","year":"2016","journal-title":"Dermatology"},{"key":"R3-21-20240829","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: Report of two cases","volume":"34","author":"Pasmatzi","year":"2011","journal-title":"Diabetes Care"},{"key":"R4-21-20240829","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1111\/j.1365-2230.2008.03204.x","article-title":"Development of bullous pemphigoid during treatment of psoriasis with adalimumab","volume":"34","author":"Stausb\u00f8l-Gr\u00f8n","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R5-21-20240829","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_794_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:17:20Z","timestamp":1787843840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_794_19"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_794_19","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}